Business Wire14d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...
Morningstar14d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
“The initiation of these additional three phase 3 trials of datopotamab deruxtecan in combination with our ... globally with AstraZeneca. Patritumab deruxtecan (HER3-DXd), a HER3 directed ...
pharmaphorum3d
AZ and Daiichi's TROP2 ADC shows promise in first-line lung cancer
In 2020, Daiichi Sankyo and AZ agreed to carry out a clinical trial exploring the combination of Tagrisso with patritumab deruxtecan in patients with this form of cancer who have specific EGFR ...
MedPage Today12d
Taking on Acquired Resistance in EGFR-Mutant NSCLC
The agent recently received FDA approval in combination with carboplatin ... The antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) is a promising treatment for EGFR inhibitor ...
Seeking Alpha19d
Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat
The other issue is KEYNOTE-189, our combination of KEYTRUDA and ... therapy (two candidates to date - ifinatamab deruxtecan (I-DXd) and patritumab deruxtecan - have delivered promising data ...
pharmaphorum29d
WCLC: Data back first-line use of Gilead, AZ/Daiichi TROP2s
which was also backed up by another study reported at WCLC for HER3 ADC patritumab deruxtecan. While the study is very small – with just 13 patients in the triple therapy arm and 14 patients on ...